Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | F2R | P25116 | 2/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9231035 | 0.95 | NR1H4 (0.56) | AKR1C3NR1H4F2RHCAR3HDAC11 | |
| SCHEMBL6330083 | 0.94 | HDAC11 (0.58) | AKR1C3NR1H4HCAR3HDAC11HDAC8 | |
| SCHEMBL6330053 | 0.94 | HDAC11 (0.58) | AKR1C3NR1H4HCAR3HDAC11HDAC8 | |
| SCHEMBL21940532 | 0.94 | HDAC11 (0.58) | AKR1C3NR1H4HCAR3HDAC11HDAC8 | |
| SCHEMBL30012465 | 0.94 | HDAC11 (0.58) | AKR1C3NR1H4HCAR3HDAC11HDAC8 | |
| SCHEMBL6332453 | 0.94 | HDAC11 (0.58) | AKR1C3NR1H4HCAR3HDAC11HDAC8 | |
| SCHEMBL873032 | 0.90 | AKR1C3 (0.61) | AKR1C3NR1H4SMN1; SMN2HCAR3 | |
| SCHEMBL11070287 | 0.86 | SOAT2 (0.52) | AKR1C3NR1H4HCAR3HDAC11HDAC8 | |
| SCHEMBL11070282 | 0.86 | SOAT2 (0.52) | AKR1C3NR1H4HCAR3HDAC11HDAC8 | |
| SCHEMBL11065030 | 0.86 | SOAT2 (0.52) | AKR1C3NR1H4HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-2021093817-A1 | IMMUNOMODULATORY COMPOUNDS, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2021-05-20 | — | — | WO | disclosed |
| US-6858565-B2 | Thermosensitive recording material and novel color developer compounds | OJI PAPER CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| US-20030040434-A1 | Thermosensitive recording material and novel color developer compounds | OJI PAPER CO., LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1264707-A2 | Thermosensitive recording material and novel color developer compounds | OJI PAPER CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-3985777-A | Sulphamyl-benzoic acid derivatives | LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB (DK) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | AKR1C3 4665/4885NR1H4 2695/4885SMN1; SMN2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.